Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 124

1.

A novel type 2N VWF gene mutation: a case report.

Evans MS, Eyster ME.

Blood Coagul Fibrinolysis. 2018 Nov;29(7):651-652. doi: 10.1097/MBC.0000000000000761.

PMID:
30036281
2.

A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

3.

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2017 Oct;15(10):1971-1976. doi: 10.1111/jth.13795. Epub 2017 Sep 14.

4.

Development of an inhibitor in a man with mild haemophilia A.

Evans MS, Eyster ME.

Haemophilia. 2017 Sep;23(5):e473-e474. doi: 10.1111/hae.13303. Epub 2017 Jul 27. No abstract available.

PMID:
28750480
5.

Development of a novel automated screening method for detection of FVIII Inhibitors.

Evans MS, Donaldson KJ, Eyster ME.

Int J Lab Hematol. 2017 Apr;39(2):185-190. doi: 10.1111/ijlh.12601. Epub 2017 Jan 30.

PMID:
28133956
6.

Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.

Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, Walsch R, Lederman M, Wang M, Hardtke M, Michaels LA.

J Thromb Haemost. 2017 Mar;15(3):411-419. doi: 10.1111/jth.13597. Epub 2017 Feb 22.

PMID:
27992112
7.

Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.

Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2016 Oct;14(10):1931-1940. doi: 10.1111/jth.13438. Epub 2016 Sep 17.

8.

Moderate X-chromosome inactivation skewing underlies factor VIII activity in symptomatic carriers from a family with mild haemophilia A.

Cygan PH, Carrel L, Eyster ME.

Haemophilia. 2016 Nov;22(6):e559-e561. doi: 10.1111/hae.13083. Epub 2016 Oct 5. No abstract available.

PMID:
27704658
9.

Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort.

Eyster ME, Kong L, Li M, Schreibman IR.

Am J Hematol. 2016 Sep;91(9):E335-40. doi: 10.1002/ajh.24427. Epub 2016 Jul 14.

10.

Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery.

Buckner TW, Leavitt AD, Ragni M, Kempton CL, Eyster ME, Cuker A, Lentz SR, Ducore J, Leissinger C, Wang M, Key NS.

Thromb Haemost. 2016 Jul 4;116(1):42-9. doi: 10.1160/TH15-10-0802. Epub 2016 Mar 24.

PMID:
27009484
11.

Anemia and the Need for Intravenous Iron Infusion after Roux-en-Y Gastric Bypass.

Kotkiewicz A, Donaldson K, Dye C, Rogers AM, Mauger D, Kong L, Eyster ME.

Clin Med Insights Blood Disord. 2015 Jun 4;8:9-17. doi: 10.4137/CMBD.S21825. eCollection 2015.

12.

Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.

Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2015 Jun;13(6):1036-42. doi: 10.1111/jth.12902. Epub 2015 May 9.

13.

Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

Gadalla SM, Preiss LR, Eyster ME, Goedert JJ.

J Viral Hepat. 2011 Mar;18(3):161-9. doi: 10.1111/j.1365-2893.2010.01289.x.

14.

Coping with the HIV epidemic 1982-2007: 25-year outcomes of the Hershey Haemophilia Cohort.

Eyster ME.

Haemophilia. 2008 Jul;14(4):697-702. doi: 10.1111/j.1365-2516.2008.01702.x. Epub 2008 Mar 25. No abstract available.

PMID:
18371164
15.

Chronic hepatitis B and other correlates of spontaneous clearance of hepatitis C virus among HIV-infected people with hemophilia.

Melendez-Morales L, Konkle BA, Preiss L, Zhang M, Mathew P, Eyster ME, Goedert JJ.

AIDS. 2007 Jul 31;21(12):1631-6.

PMID:
17630559
16.

Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs.

Eyster ME, Asaad SM, Gold BD, Cohn SE, Goedert JJ; Second Multicenter Hemophilia Study Group.

Haemophilia. 2007 May;13(3):279-86.

PMID:
17498077
17.

HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.

Shire NJ, Horn PS, Rouster SD, Stanford S, Eyster ME, Sherman KE; Multicenter Hemophilia Cohort HCV Study Group.

Hepatology. 2006 Nov;44(5):1146-57.

PMID:
17058240
18.

Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.

Tsoukas C, Eyster ME, Shingo S, Mukhopadhyay S, Giallella KM, Curtis SP, Reicin AS, Melian A.

Blood. 2006 Mar 1;107(5):1785-90. Epub 2005 Nov 15.

19.

Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia.

Zhang M, Rosenberg PS, Brown DL, Preiss L, Konkle BA, Eyster ME, Goedert JJ; Second Multicenter Hemophilia Cohort Study.

Blood. 2006 Feb 1;107(3):892-7. Epub 2005 Oct 4.

20.

Knee and hip arthroplasty infection rates in persons with haemophilia: a 27 year single center experience during the HIV epidemic.

Powell DL, Whitener CJ, Dye CE, Ballard JO, Shaffer ML, Eyster ME.

Haemophilia. 2005 May;11(3):233-9.

PMID:
15876268

Supplemental Content

Loading ...
Support Center